Arctic Vision, a China-based clinical-stage ophthalmology company developing innovative therapies for pan-ocular diseases, Tuesday announced the completion of over $100 million in a Series B funding round led by private equity (PE) firm Loyal Valley Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
